Bolivia Ley 1737 Medical Device Scope: How the Medicines Law Covers Devices

1. Key takeaways

Bolivia has no standalone medical device law. Medical devices stand alongside medicines, biological products, vaccines, blood products, medical foods, cosmetics, dental products, homeopathic products, and natural and traditional medicinal products in the scope of application of Article 2 of the Medicines Law, Ley N° 1737 of December 17, 1996. This legislative choice produces three direct consequences. First, device rules can only be elaborated through ministerial resolutions rather than through dedicated legislation. Second, the professional background of responsible officials is designed around the pharmaceutical system. Third, the pricing and speculation provisions (Article 1(e) and Article 59) apply to devices equally. GRZAN’s assessment is that understanding this point is the prerequisite for understanding why every Bolivian device rule looks the way it does, because the instruments, the forms, the fees, and the enforcement habits all inherit the vocabulary and the institutional logic of a medicines law.

For importers and distributors, the consequence shows up in daily paperwork rather than in the law books. The certificate issued for a device is a sanitary registration under the same regime as a medicine, the reviewing officers are organized around a pharmaceutical agency, and the forms, circulars, and price lists that govern the product are published through the channels of the medicines system. A device program in Bolivia therefore needs a regulatory lead who can read the medicines framework fluently, anticipate which pharmaceutical-style obligations will be extended to devices, and translate them into device project plans. Companies that staff the market with device-only expertise tend to discover these inherited obligations late, usually at the point where an observation letter cites an article of the Medicines Law that nobody on the team has read.

2. Legal basis

3. Expert insights

Insight one: a lower rule hierarchy means weaker stability. Because device rules cannot become an independent law, they are carried by ministerial resolutions (Resolución Ministerial) and by the registration manual. The amendment threshold for a ministerial resolution is lower than for a law, which means that the enforcement interpretation can change without any legislative procedure. Relying on application experience gathered several years ago is therefore a high-risk strategy, and any dossier strategy built on precedent should be revalidated against the current text before submission.

Insight two: Article 1(e) and Article 59 are the real levers of device pricing compliance. Article 1(e) requires the national medicines policy to establish decentralized mechanisms for procurement, supply, dispensing, and control of the country-of-origin prices of imported medicines. Article 59 lists violations of the law and its regulation, including speculation and hoarding, as punishable conduct. When AGEMED issued its price list on January 6, 2021 through Circular MSyD/AGEMED/CR/1/2021, it cited precisely these two provisions. Device companies that assume pricing compliance concerns only medicines will find themselves on the defensive in public procurement, where price lists directly condition eligibility to bid and to hold framework agreements.

Insight three: the same law does not mean the same dossier. Although devices are written into the medicines law, the application forms are separate: medicines use Form 005, while devices use Form 027. Confusing the two documentation systems is a common and entirely avoidable reason for rejection at intake, and it signals to the reviewer that the applicant has not studied the Bolivian system itself.

Insight four: the medicines-law framing defines the language of every certificate and letter. Because devices are regulated inside Ley N° 1737, the vocabulary of Bolivian device compliance is pharmaceutical vocabulary: registro sanitario, circular, resolution, and the enterprise-level obligations that surround the certificate holder. This matters when drafting responses to reviewer observations, because an answer written in the terminology of another regulatory system reads as foreign and slows the exchange. GRZAN prepares submissions and correspondence in the terminology of the law itself, which shortens review rounds and reduces the number of clarification requests an applicant receives.

4. Practical recommendations

The recommendations below follow from the three consequences described in the takeaways: the low hierarchy of device rules, the reach of the pricing provisions, and the separation of the device documentation system. Each one can be implemented without additional cost if it is built into the project from the beginning, and each one becomes expensive if it is introduced after a rejection or an observation letter has already been issued.

1. Bring pricing compliance into registration planning instead of post-market remediation. Public procurement is the main channel for devices in Bolivia, and the price list system directly affects tender eligibility.
2. Establish a tracking mechanism for ministerial resolutions. Because the rules sit at a low hierarchy and move quickly, GRZAN recommends adding the resolutions and circulars section of the AGEMED website to a quarterly review list, at a frequency higher than the tracking applied to neighboring jurisdictions.
3. Do not reuse the medicines dossier architecture. Form 027 for devices and the technical documentation requirements of Section 2.4 of the manual form a self-contained system with its own logic.

As a closing note on scope: the enumeration in Article 2 is the same enumeration that the rest of the Bolivian health-products system uses, so the classification of a product in the law also determines which procedure, which fee schedule, and which review desk the product meets. Confirming the category early, in writing, avoids the situation where a product is prepared as a device, reaches the reviewing office, and is redirected to a different regime with different forms and different evidence expectations.

5. Verification checklist

• □ Confirm the specific category listed in Article 2 of Ley N° 1737 to which the target product belongs
• □ Confirm that Form 027 (devices) is used rather than Form 005 (medicines)
• □ Confirm whether the target product falls within the scope of the AGEMED price list
• □ Confirm the applicability of the speculation and hoarding provisions of Article 59 to the commercial model of this project
• □ Check whether the AGEMED website has published any new ministerial resolution or circular

Regulatory information verified as of October 29, 2026.

GRZAN supports manufacturers, importers, and authorized representatives with medical device registration in Bolivia, covering dossier preparation, local entity coordination, and regulatory strategy. Contact info@grzanglobal.com for project inquiries.